文献速递白血病

阿扎胞苷联合维奈克拉治疗不适合强化疗初治AML的成本效果

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

研究基于VIALE-A试验构建分区生存模型,从美国支付方角度比较阿扎胞苷联合维奈克拉与阿扎胞苷单药治疗不适合强化疗的初治AML的成本与效果。联合方案增加0.61个质量调整生命年,但增量成本达159 595美元,ICER为每QALY 260 343美元,需维奈克拉降价60%才能在每QALY 150 000美元阈值下具成本效果。

要点

  • 联合方案增加0.61 QALY,增量成本159 595美元,ICER为260 343美元/QALY。
  • 在150 000美元/QALY支付阈值下,维奈克拉需降价60%才具成本效果。
  • 现行价格下该联合方案用于不适合强化疗初治AML不太可能具成本效果。

核心结论

  • 现行价格下,阿扎胞苷联合维奈克拉治疗不适合强化疗的初治AML不太可能具成本效果。
  • 需维奈克拉大幅降价才能将ICER降至更广泛可接受的水平。

研究设计与样本

  • 基于VIALE-A试验数据构建分区生存模型,比较阿扎胞苷联合维奈克拉与阿扎胞苷单药。
  • 无进展生存与总生存曲线通过参数生存模型从VIALE-A试验推导。
  • 从美国支付方角度计算增量成本效果比(ICER)。

主要发现

  • 联合方案较阿扎胞苷单药增加0.61个质量调整生命年(QALY)。
  • 联合方案终身医疗费用显著更高,增量成本为159 595美元。
  • ICER为每QALY 260 343美元。

关键数值与推荐

  • 维奈克拉价格需下降60%,才能在每QALY 150 000美元的支付意愿阈值下具成本效果。

临床怎么用

  • 评估该联合方案用于不适合强化疗初治AML时,应结合药品价格与支付阈值考量成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 VIALE-A trial reported that venetoclax in combination with azacitidine significantly improved response rates and overall survival compared with azacitidine alone in older, unfit patients with previously untreated acute myeloid leukemia (AML). However, the cost-effectiveness of azacitidine-venetoclax in this clinical setting is unknown. In this study, we constructed a partitioned survival model to compare the cost and effectiveness of azacitidine-venetoclax with azacitidine alone in previously untreated AML. Event-free and overall survival curves for each treatment strategy were derived from the VIALE-A trial using parametric survival modeling. We calculated the incremental cost-effectiveness ratio (ICER) of azacitidine-venetoclax from a US-payer perspective. Azacitidine-venetoclax was associated with an improvement of 0.61 quality-adjusted life-years (QALYs) compared with azacitidine alone. However, the combination led to significantly higher lifetime health care costs (incremental cost, $159 595), resulting in an ICER of $260 343 per QALY gained. The price of venetoclax would need to decrease by 60% for azacitidine-venetoclax to be cost-effective at a willingness-to-pay threshold of $150 000 per QALY. These data suggest that use of azacitidine-venetoclax for previously untreated AML patients who are ineligible for intensive chemotherapy is unlikely to be cost-effective under current pricing. Significant price reduction of venetoclax would be required to reduce the ICER to a more widely acceptable value.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Patel KK, Zeidan AM, Shallis RM, et al. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021. PMID: 33591323. doi:10.1182/bloodadvances.2020003902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。